ARTICLE | Product Development
Biogen plots pipeline strategy as CEO readies to depart
Interim head of R&D says the biotech plans to stay the course in neuroscience, at least for now
May 4, 2022 1:30 AM UTC
With Head of R&D Alfred Sandrock gone and CEO Michel Vounatsos leaving, Biogen has an opportunity to remake itself. The company is already cutting costs following Aduhelm’s market failure, but its next decisions will determine whether this moment is the start of the company’s phoenix act.
On Tuesday, Biogen Inc. (NASDAQ:BIIB) announced Vounatsos will step down once a replacement is identified. The news comes a few months after Sandrock, who shepherded development of Aduhelm aducanumab-avwa, left the company. Biogen has yet to hire a Sandrock replacement. Priya Singhal, head of global safety and regulatory sciences, is serving as interim head of R&D...